2 hasil untuk "the Nirsevimab Effectiveness Study Collaborators"
Menampilkan 1–2 · 0,53 detik · RSS
-
Artikel Jurnal
Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025
BACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations throughout two seasons in healthy term-born…
-
Artikel Jurnal
Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season
Background Respiratory syncytial virus (RSV) causes substantial morbidity in infants